Quantitative Western blot analyses showed a significant reduction in IGF2 in hippocampal samples from patients with AD (n = 8) (Braak stage V-VI) compared to non-AD control subjects (n = 5) of a similar age and sex (Fig2A). This evidence concerns the gene IGF2 and Alzheimer disease.